Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment

Conclusion: Secondary prophylaxis with dalteparin is a cost-effective alternative to VKA for the prevention of recurrent VTE in patients with cancer.
Source: Clinical and Applied Thrombosis/Hemostasis - Category: Hematology Authors: Tags: Original Articles Source Type: research